Inherited Risk & Protection12x Family Cirrhosis Rule
Laboratory-Based Biomarkers • Differential & Genetic Workup

Genetics (PNPLA3, TM6SF2, HSD17B13) & Family Cirrhosis Screening

How inherited lipid-droplet genes modify MASH progression, when genetic testing helps, and why first-degree relatives of MASLD-cirrhosis patients need elastography screening.

What This Means for Patients

Why does one person live with mild liver fat for 40 years without a trace of scar tissue, while a sibling with the exact same weight and diet develops MASH cirrhosis in their 50s? Genetics supplies a huge piece of that puzzle — led by common variants in PNPLA3, TM6SF2, MBOAT7, and SERPINA1 that trap fat droplets inside liver cells, balanced against naturally protective variants like HSD17B13.

Even without ordering a DNA panel, family history itself is one of the strongest diagnostic tools we have: if your parent, brother, sister, or adult child has cirrhosis from MASLD/MASH, your own odds of silent advanced fibrosis are roughly 12 times higher than average — and AASLD recommends going straight to a liver stiffness scan (FibroScan or MRE) rather than relying on normal liver enzymes.

Actionable Family Screening Mandate (AASLD 2023 & AGA): 12× Cirrhosis Risk in First-Degree Relatives

Prospective family-cohort studies show that parents, full siblings, and adult children of a patient with MASLD-cirrhosis have a ~12-fold higher risk of advanced fibrosis (≥F3) (~15%–18% prevalence vs. ~1%–2% in the general population) — often with completely normal ALT and AST levels.1,2 AASLD explicitly recommends counseling first-degree relatives of MASLD-cirrhosis patients and screening them directly with elastography (VCTE or MRE).1

Major Inherited Variants Shaping MASLD, MASH, and Cirrhosis Risk1,3–6

Gene & Variant Biological Mechanism Clinical Effect on Liver & Lipids Population Context
PNPLA3 I148M
(rs738409 C>G)
Mutant patatin-like phospholipase accumulates on lipid droplets and traps polyunsaturated triglycerides inside hepatocytes & stellate cells3 Strongest common genetic driver: ~2×–3.5× higher risk of MASH, bridging fibrosis, cirrhosis, and HCC; multiplicative synergy (>5×–10×) with obesity, T2D, or alcohol1,3 Present in ~45%–50% of Hispanic/Latino individuals vs. ~23% European and ~15% African ancestry, explaining higher MASH severity even at lower BMI.1,3
TM6SF2 E167K
(rs58542926)
Impairs hepatic VLDL triglyceride export from the endoplasmic reticulum4 The Lipid–Liver Paradox: lowers circulating LDL cholesterol and triglycerides (reducing heart attack risk) while increasing hepatic fat, MASH fibrosis, and HCC risk4 Carrier frequency ~7% (European ancestry); explains why some severe MASH patients have “reassuringly low” cholesterol panels.
MBOAT7 & GCKR
(rs641738 / P446L)
Altered phosphatidylinositol acyl-chain remodeling (MBOAT7) and unregulated hepatic de novo lipogenesis from glucose (GCKR)3 Modestly increases steatosis, lobular inflammation, and fibrosis progression, particularly in polygenic risk scores Common modifiers across European, Asian, and admixed cohorts; intensifies sensitivity to dietary refined carbohydrates/fructose.
HSD17B13 LoF
(rs72613567 splice)
Loss-of-function in lipid-droplet retinol/estradiol dehydrogenase reduces inflammatory bioactive lipid signaling5 Protective Variant: lowers risk of MASH inflammation, F3–F4 fibrosis, and HCC by ~30%–50%, blunting injury even in PNPLA3 I148M carriers5 Inspired a new class of investigational RNAi therapeutics silencing HSD17B13 to mimic natural genetic resilience.
SERPINA1 PI*Z
(Glu342Lys / PI*MZ)
Misfolded alpha-1 antitrypsin polymers accumulate inside hepatocyte ER6 Heterozygous PI*MZ carrier state acts as a potent “second hit,” doubling to tripling cirrhosis and hepatic decompensation risk in MASLD6 Carried by ~2%–4% of Northern European descendants; screen with AAT level + PI phenotype.

Should Every MASLD Patient Order PNPLA3 Testing Today?

  • Routine primary care: Not yet required. Both AASLD (2023) and EASL (2024) state that routine population genotyping is not yet recommended because management still hinges on phenotypic fibrosis staging (FIB-4, VCTE, ELF, MRE).1,4
  • When academic centers DO consider genetics: Lean MASLD (BMI <25), early-onset or cryptogenic cirrhosis, discordant NITs, strong multi-generation liver disease clustering, or clinical trial enrollment.

What If 23andMe / Consumer DNA Shows PNPLA3 GG?

  • Genes are not destiny: Even homozygous PNPLA3 I148M (GG) causes minimal scarring when visceral adiposity, insulin resistance, and alcohol are kept low — and studies show PNPLA3 GG carriers actually experience larger liver-fat drops from weight loss and dietary sugar reduction than non-carriers!3
  • Bring the result to your clinician to ensure baseline FIB-4 and elastography staging are completed and alcohol is minimized.